Professor Nyström has nearly 30 years of experience in the field of cancer research and especially the most common inherited cancer syndrome, Lynch syndrome (LS, prev. Hereditary Non-Polyposis Colorectal Cancer, HNPCC).

At present, our research has two main interests; colon transcriptome changes in cancer development and diagnosis of an inherited mismatch repair (MMR) deficiency. The transcriptome project focuses on cancer related biomarkers occurring as the cancer preceding field defect in normal colon mucosa. The research project of the functional assessment of MMR efficiency in normal healthy cells has given rise to the commercial DiagMMR®, the Lynch syndrome carrier test for sale at LS CancerDiag Ltd (https://www.lscancerdiag.com/)

These projects originate from the ERC AdG 232635 “Epigenome and Cancer Susceptibility”, and ERC Proof of Concept Grant 2012‐324604, which both focused on early detection and prevention of cancer (https://blogs.helsinki.fi/episusceptibility/about-the-project/).